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Objectives: To investigate the molecular epidemiology, antimicrobial susceptibility and carbapenem resistance
determinants of Acinetobacter baumannii isolates from respiratory tract samples of patients diagnosed with
ventilator-associated pneumonia (VAP) who were enrolled in the MagicBullet clinical trial.
Methods: A. baumannii isolates were prospectively cultured from respiratory tract samples from 65 patients
from 15 hospitals in Greece, Italy and Spain. Susceptibility testing was performed by broth microdilution.
Carbapenem resistance determinants were identified by PCR and sequencing. Molecular epidemiology was
investigated using rep-PCR (DiversiLab) and international clones (IC) were identified using our in-house
database.
Results: Of 65 isolates, all but two isolates (97%) were resistant to imipenem and these were always associated
with an acquired carbapenemase, OXA-23 (80%), OXA-40 (4.6%), OXA-58 (1.5%) or OXA-23/58 (1.5%).
Resistance to colistin was 47.7%. Twenty-two isolates were XDR, and 20 isolates were pandrug-resistant (PDR).
The majority of isolates clustered with IC2 (n"54) with one major subtype comprising isolates from 12 hospitals
in the three countries, which included 19 XDR and 16 PDR isolates.
Conclusions: Carbapenem resistance rates were very high in A. baumannii recovered from patients with VAP.
Almost half of the isolates were colistin resistant, and 42 (64.6%) isolates were XDR or PDR. Rep-PCR confirmed
IC2 is the predominant clonal lineage in Europe and suggests the presence of an epidemic XDR/PDR A. baumannii
clone that has spread in Greece, Italy and Spain. These data highlight the difficulty in empirical treatment of pa-
tients with A. baumannii VAP in centres with a high prevalence of carbapenem-resistant A. baumannii.
Introduction
Considered susceptible to major antimicrobial drug classes in the
1970s, the clinical importance of the Gram-negative, nosocomial
pathogen Acinetobacter baumannii has increased steadily and
today this organism is displaying resistance against all first-line
antibiotics.1,2 Owing to its intrinsic antimicrobial resistance and its
ability to easily acquire new resistance determinants, MDR, XDR
and even pandrug-resistant (PDR) isolates have now been
described.1–4 A. baumannii has established a niche in healthcare
environments where it is involved in a variety of serious infections,
particularly in patients with severe comorbidities in the ICU set-
ting.1,2 Infections include ventilator-associated-pneumonia (VAP),
bloodstream infection, as well as wound and urinary tract infec-
tion, meningitis and soft tissue infection.1,5 Of these, VAP is the
most frequent healthcare-associated infection.6 It is associated
with excess mortality, excess length of ICU and hospital stay,
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prolonged mechanical ventilation and therefore higher overall
costs.6,7 The predominant organisms in nosocomial pneumonia
are Staphylococcus aureus and aerobic Gram-negative bacilli
(GNB), predominantly Pseudomonas aeruginosa, Enterobacteria-
ceae and A. baumannii.6,8 Given the high prevalence of MDR GNB,
adequate empirical antimicrobial therapy for VAP is difficult to es-
tablish and inappropriate treatment is associated with a poor prog-
nosis in these patients.9 Carbapenem monotherapy or combined
with an aminoglycoside or a quinolone has become a widely
applied empirical therapy.10,11 However, often this strategy may
not be successful as many GNB occurring in ICU settings now ex-
hibit resistance to all three antimicrobial classes.12
Owing to a lack of new antimicrobial agents, the old off-patent
drug colistin has come into consideration again, showing good
in vitro activity against carbapenem-resistant GNB (CR-GNB).13
To date, the clinical efficacy of colistin has been suggested in ex-
perimental models and clinical case series but no clinical trial using
colistin as empirical treatment for VAP has been carried out.14,15
Therefore, in 2012 the Phase IV, randomized, open-label, non-
inferiority, international clinical trial MagicBullet was initiated to as-
sess the safety and efficacy of colistin versus meropenem in the
empirical treatment of VAP.16 The study was conducted over
4 years and included 32 centres in Spain, Italy and Greece, coun-
tries with a high incidence of infections caused by CR-GNB. As part
of this trial it was the aim of this study to characterize the molecu-
lar epidemiology, antimicrobial susceptibility and carbapenem re-
sistance mechanisms of A. baumannii isolates recovered from
respiratory tract samples from patients with VAP.
Materials and methods
Bacterial isolates
One hundred and twenty-four A. baumannii isolates were collected from
respiratory tract samples (bronchoalveolar lavage or bronchial aspirates)
from 65 patients diagnosed with VAP from seven hospitals in Greece
(70 isolates), five hospitals in Spain (28 isolates) and three hospitals in
Italy (26 isolates) between May 2012 and September 2015 as part of the
clinical trial MagicBullet (ClinicalTrials.gov NCT01292031). Samples were
taken before initiation of any empirical treatment for VAP, and thereafter
if available at 72 h, at day 8, at the end of antibiotic treatment, and at day
28 of follow-up. Species identification and susceptibility testing were per-
formed according to local standards. Acinetobacter isolates were then
sent to the central laboratory for further investigation. Species identifica-
tion was confirmed by gyrB multiplex PCR as described previously.17
Antimicrobial susceptibility testing
The following antibacterial agents were tested (respective concentration
ranges are given in parentheses): amikacin (0.125–256 mg/L); ampicillin/sul-
bactam (0.25/0.125–256/128 mg/L); cefepime (0.125–256 mg/L); colistin
(0.03–256 mg/L); cotrimoxazole (0.06–32 mg/L); doxycycline (0.03–32 mg/L);
imipenem (0.125–256 mg/L); levofloxacin (0.03–64 mg/L); meropenem
(0.125–256 mg/L); minocycline (0.06–128 mg/L); sulbactam (0.06–128 mg/L);
tigecycline (0.03–64 mg/L); and tobramycin (0.06–128 mg/L). Antimicrobial
susceptibility testing was performed by standard broth microdilution in
CAMHB according to the international standard ISO 20776-1.18 Microtitre
plates containing dehydrated antibacterial agents were purchased from
Merlin Diagnostica (Bornheim-Hersel, Germany). Plates were incubated
at 35+1 C for 18+2 h and read visually. Escherichia coli ATCC 25922
and P. aeruginosa ATCC 27853 were used as quality control strains. MICs
were interpreted according to the species-specific clinical breakpoints
approved by EUCAST (Version 7.0, January 2017).19 As no susceptibility break-
point for tigecycline is available for A. baumannii, the EUCAST breakpoint
for Enterobacteriaceae was used instead (susceptible 1 mg/L; resistant
4 mg/L). Classification of MDR, XDR and PDR was based on current EUCAST
breakpoints for Acinetobacter spp., i.e. not including tigecycline using the fol-
lowing ad-hoc definition; MDR, resistant to at least one antibiotic from three
classes tested; XDR, resistant to all antibiotics tested except one; PDR, resistant
to all antibiotics tested.
PCR and sequencing of blaOXA genes
Detection of intrinsic and acquired OXA-type carbapenemases and pres-
ence of IS elements adjacent to genes encoding OXA-51-like, OXA-23-like
and OXA-58-like was performed by PCR and blaOXA genes were sequenced
using primers as previously described.20,21
Molecular epidemiology
The molecular epidemiology of the isolates was determined by repetitive
sequence-based PCR (DiversiLabTM System; bioMe´rieux).17 Clonal related-
ness was analysed with the DiversiLab software using the Pearson correl-
ation statistical method. Isolates showing 98% similarity in their rep-PCR
pattern were considered identical. Using the modified Kullback–Leibler stat-
istical method, isolates were assigned to international clones (IC) using our
in-house database and isolates that clustered at .95% were considered
related to the IC.17
Results
Bacterial isolates
Of the total 124 Acinetobacter isolates that were confirmed as
A. baumannii using the gyrB multiplex PCR, 65 were selected based
on being the first isolate per patient and analysed. Among these
65 isolates, the majority were collected before initiation of empirical
antimicrobial treatment (DT0, n"26) or within 72 h of treatment
(DT3; n"16). The remaining isolates were recovered at 8 days of
treatment (DT8; n"11), at the end of antibiotic treatment (DT-F;
n"8) and at 28 days of follow-up (DT28; n"4). All following data
are based on the first isolate per patient, i.e. 65 isolates.
Antimicrobial susceptibility
Antimicrobial susceptibility results are summarized in Table 1.
The vast majority of isolates (96.9%) were determined to be re-
sistant to imipenem, with the exception of two isolates, one each
from Italy and Greece. Thirty-one isolates (47.7%) were resistant
to colistin and 34 isolates were susceptible, with an MIC50 of
2 mg/L and MIC90 of 256 mg/L. Isolates from Greece exhibited the
highest rate of colistin resistance (56.8%), whereas isolates from
Italy and Spain had resistance rates of 42.9% and 28.6%, respect-
ively. Furthermore, four, two and one isolates from Greece, Italy
and Spain had colistin MICs 256 mg/L, respectively. Regarding
tigecycline, five isolates exhibited a resistant phenotype (7.7%),
23 were intermediate (35.4%) and 37 isolates (56.9%) were con-
sidered susceptible. Tigecycline MIC50 and MIC90 values were
1 and 2 mg/L, respectively.
Susceptibility testing against the other antibiotics revealed high
overall resistance rates to the aminoglycosides and levofloxacin
(Table 1). One isolate was fully susceptible to all antibiotics tested,
21 were considered MDR, 22 were XDR and 20 were PDR. There
was no difference in resistance rates by country (data not shown).
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Detection of carbapenemases
The A. baumannii isolates were investigated for the presence of
intrinsic and acquired OXA-type carbapenemases (Table 2).
Among the intrinsic OXA-51 subclass, OXA-66 was predominant,
present in 54 of 65 isolates (83%) collected from all three coun-
tries. Five isolates from Greece had OXA-69, whereas three iso-
lates from Italy carried OXA-82, which was associated with
ISAba1 encoded upstream. Furthermore, two isolates from one
hospital in Spain harboured OXA-387. A single carbapenem-
susceptible isolate from Italy was found to carry OXA-391, and
no further acquired OXA-type carbapenemases were detected
in this isolate. Similarly, one of the OXA-69 harbouring isolates
did not carry any additional OXA, and was susceptible to the
carbapenems.
Among the acquired carbapenem resistance genes, OXA-23
associated with ISAba1 encoded upstream was found in 80%
(n"52) of isolates. OXA-58 associated with ISAba3 (n"6) was
found in Spain and Italy, and OXA-40 (n"3) was only detected in
isolates from Spain; only one isolate from Italy harboured OXA-58.
Furthermore, one isolate from Athens, Greece harboured both
OXA-23 and OXA-58.
Molecular epidemiology
The majority of the isolates clustered with international clonal lin-
eages IC1 and IC2 (Table 3). Five isolates from Greece clustered
with IC1 strains from our in-house database, four of which were
from one hospital in Greece and showed98% similarity (cluster A;
Figure 1). Eighty-three per cent of isolates (n"54) exhibited a rep-
PCR pattern characteristic for IC2 strains, 53 of which clustered with
98% similarity (cluster B) and comprised isolates from all three
countries, and one isolate displayed a unique rep-PCR pattern.
Sixteen of 20 PDR isolates and 19 of 22 of the XDR isolates were
from cluster B. Furthermore, six isolates from Italy and Spain could
not be assigned to any of the eight previously described ICs and
were considered genotypically unique. Of these, three isolates from
two hospitals in Italy formed cluster C (all were PDR), two isolates
from one hospital in Spain represented cluster D, and one isolate
from Italy had a unique rep-PCR pattern.
All IC1 isolates had the OXA-69 variant encoded on the chromo-
some, whereas all IC2 isolates had the OXA-66 variant. Isolates
harbouring OXA-82, OXA-387 or OXA-391 each had a genotypically
unique rep-PCR pattern.
Thirty patients were treated with colistin, of which 18 had
strains resistant to colistin, compared with 13 of 35 colistin-
resistant strains in patients who were treated with meropenem.
Typing showed that there was sometimes more than one colistin-
resistant strain within a hospital, suggesting that resistance was
developing independently. Furthermore, we observed in some
hospitals that colistin-resistant clones persisted over time and
were recovered from patients irrespective of the patient receiving
meropenem or colistin. We also observed colistin-resistant isolates
first appearing in meropenem-treated patients and the strain
spreading to other patients.
Table 1. Susceptibility data of A. baumannii isolates (first isolates only,
n"65) collected from patients with VAP in Greece, Italy and Spain
Antimicrobial agent MIC50
a MIC90 Range %S
b %I %R
Amikacin .256 .256 1–.256 6.2 7.7 86.1
Ampicillin/sulbactam 32/16 64/32 1/0.5–128/64 – – –
Cefepime 64 128 2–.256 – – –
Colistin 2 256 0.25–.256 52.3 – 47.7
Cotrimoxazole 32 .32 0.125–.32 26.2 1.5 72.3
Doxycycline .32 .32 0.125–.32 – – –
Imipenem 32 64 0.25–128 1.5 1.5 96.9
Levofloxacin 16 64 0.125–.64 1.5 – 98.5
Meropenem 64 64 0.25–128 3.1 9.2 87.7
Minocycline 8 16 0.125–16 – – –
Sulbactam 16 32 1–64 – – –
Tigecyclinec 1 2 0.125–8 56.9 35.4 7.7
Tobramycin .128 .128 0.125–.128 21.5 – 78.5
aMIC values are given in mg/L.
bS, susceptible; I, intermediate; R, resistant; –, no EUCAST breakpoint
available.
cEnterobacteriaceae breakpoints were applied for tigecycline MIC inter-
pretation; S1 mg/L; R4 mg/L.
Table 2. Percentage of isolates (n"65) with the following intrinsic and
acquired OXA-type carbapenemases
OXA-type Percentage of isolates
Intrinsic carbapenemases
OXA-66 83.1
OXA-69 7.7
OXA-82a 4.6
OXA-387 3.1
OXA-391 1.5
Acquired carbapenemases
OXA-23a 80.0
OXA-40 4.6
OXA-58b 10.8
OXA-23a/OXA-58b 1.5
none 3.1
aAssociated with ISAba1.
bAssociated with ISAba3.
Table 3. Molecular typing and clustering of 65 A. baumannii isolates
Lineage
rep-PCR
cluster
No. of
isolates
Country
(no. of hospitals)
IC1 A 4 Greece (1)
singleton 1 Greece (1)
IC2 B 53 Spain (4), Italy (2),
Greece (6)
singleton 1 Spain (1)
Genotypically
unique
C 3 Italy (2)
D 2 Spain (1)
singleton 1 Italy (1)
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Discussion
The prevalence of MDR, XDR and in particular PDR A. baumannii is
increasing worldwide, limiting the treatment options for infected
patients. As part of the MagicBullet clinical trial, this study charac-
terized A. baumannii isolates recovered from respiratory tract sam-
ples from patients with VAP to gain insights into the current clinical
epidemiology of A. baumannii isolates from southern European
countries (Greece, Italy and Spain), which are notorious for a high
incidence of MDR and XDR A. baumannii.
In our A. baumannii isolates, we found a clear predominance of
IC2, which is widely distributed around the world.17 Furthermore,
in longitudinal studies carried out over a 10 year period in Greece
and Spain, a shift from other lineages, in particular from IC1 to IC2
has been observed,22,23 and only five isolates from two hospitals in
Greece belonged to IC1 in our study.
IC1 and IC2 isolates encoded the intrinsic OXA-type carbapene-
mase genes blaOXA-69 or blaOXA-66, respectively, as previously
described.24 It has been suggested that the emergence of these
two lineages may play a role in the spread of carbapenem resist-
ance, due to the acquired carbapenemases they harbour,25 and
we found with only one exception, all isolates assigned to IC1 or
IC2 were resistant to carbapenems. The resistant phenotype was
always associated with acquired carbapenemases, with OXA-23
being the most prevalent. OXA-23 was first described in Italy,
Greece and Spain in 2009, 2011 and 2013, respectively, and has
now almost completely replaced OXA-58 in these countries, a phe-
nomenon that has also been described in other countries.25–28
Overall, carbapenem resistance was almost universal in the iso-
lates from our study confirming or even exceeding the resistance
rates reported previously in the three countries.29–31 This spread
and high incidence of carbapenem-resistant isolates has been
attributed to the extensive use of carbapenems for the treatment
of infections caused by MDR Gram-negative bacteria, including
A. baumannii. In addition, carbapenem-resistant isolates within
the present study also exhibited high resistance rates to other
b-lactams, aminoglycosides, fluoroquinolones, tetracyclines (with
the exception of tigecycline) and cotrimoxazole as previously re-
ported.29 For these reasons, tigecycline and, in particular, colistin,
were considered last resort antimicrobials for the treatment of pa-
tients infected with CR A. baumannii.29,30 However, over the course
of this study, colistin resistance rates were already initially high
and increased from 32% in 2012–13, to 62% in 2014–15, respect-
ively. Colistin resistance is still relatively rare in A. baumannii al-
though this might be due to the difficulties in susceptibility testing.
A recent study suggests that colistin resistance is greatly underes-
timated using commercial susceptibility testing methods.32 We do
not have the original laboratory-generated colistin susceptibility
data for all the strains in this study. Where we have these data, of
38 samples, 5 recorded higher MICs in the local laboratories com-
pared with broth microdilution, and these 5 were shown to be
falsely reported as resistant. Thirty isolates recorded lower MICs in
the local laboratories compared with broth microdilution and of
these, 18 were shown to be falsely reported as susceptible. Four
isolates recorded the same MICs as reported by the local
IC1; A
OXA-69
IC2; B
OXA-66
IC1; singleton
OXA-69
IC2; singleton
OXA-66
GtU; C
OXA-82
Gridline Spacing: 5% Similarity
GtU; D
OXA-387
GtU; singleton
OXA-391
Figure 1. DiversiLab scatterplot of 65 A. baumannii isolates with their respective DiversiLab clustering and intrinsic blaOXA. GtU, genotypically unique;
A–D, clusters, based on rep-PCR typing.
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laboratory and broth microdilution. These data reinforce the idea
that colistin resistance is probably underreported. We found that
the highest incidence of colistin resistance was from Greece, and in
a recent study 27% of A. baumannii from Greece were colistin re-
sistant, while in Germany, a PDR strain was isolated from a patient
who had been hospitalized in Greece.4,33
Although there is a published definition for PDR,34 we did not
apply this to the present study because many of the antibiotics
listed have no EUCAST breakpoint values set for Acinetobacter spp.
The XDR and PDR isolates we found in all three countries had very
similar rep-PCR patterns suggesting clonal relatedness. Previously
we have witnessed the importation of a PDR strain from Greece
into Germany, which highlights the danger these organisms pose
not only in their country of origin, but globally.4
In conclusion, among A. baumannii isolates recovered from pa-
tients with VAP in southern Europe, carbapenem resistance was al-
most universal. Alarmingly, 32% (n"21) of isolates were MDR,
34% (n"22) were XDR and 31% (n"20) PDR, highlighting the dif-
ficulty in selecting antimicrobial treatment regimens for patients
with A. baumannii VAP. Rep-PCR revealed IC2 as the predominant
lineage with 82% of isolates grouping in one large cluster, which
included the majority of the PDR isolates, suggesting the presence
of an epidemic PDR A. baumannii clone that has spread within
Greece, Italy and Spain.
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